• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

January 15, 2018
Company Drug/Device Medical Condition Status
Chimerix brincidofovir adenovirus infection related to pediatric transplant Phase I trials initiated in 141 subjects in the U.S. and Europe
Oncolix Prolanta advanced ovarian cancer Phase I trials initiated
Immix Biopharma IMX-110 advanced Solid Tumors Phase I/IIa trials planned
Aptevo Therapeutics otlertuzumab peripheral T-cell lymphoma Phase II trials initiated enrolling 24 subjects
Novaliq NOV03 dry eye disease Phase II trials initiated
Akcea Therapeutics AKCEA-APOCIII-LRx hypertriglyceridemia, established cardiovascular disease Phase IIb trials initiated
CymaBay Therapeutics seladelpar primary biliary cholangitis Phase II/III trials initiated
Minoryx Therapeutics MIN-102 adrenomyeloneuropathy Phase II/III trials initiated globally
Semnur Pharmaceuticals SP-102 lumbar radicular pain/sciatica Phase III trials initiated enrolling 400 subjects in the U.S.
Semnur Pharmaceuticals SP-102 lumbar radicular pain/sciatica Fast Track designation granted by the FDA
Avadel Pharma FT 218 narcolepsy Orphan Drug designation granted by the FDA
Spruce Biosciences SPR001 congenital adrenal hyperplasia Orphan Drug designation granted by the EMA
AbbVie upadacitinib (ABT-494) moderate to severe atopic dermatitis Breakthrough Therapy designation granted by the FDA
Global Blood Therapeutics voxelotor sickle cell disease Breakthrough Therapy designation granted by the FDA
Amgen Xgeva (denosumab) prevention of skeletal-related events in patients with multiple myeloma FDA expanded approval

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing